Auris Medical to Announce First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 11, 2016
May 04 2016 - 8:09AM
Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology, today announced that it will
report its financial results for the first quarter of 2016 on
Wednesday, May 11, 2016. Following the announcement, Auris
Medical's management team will host a live conference call and
webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to
discuss the Company's financial results and to provide a general
business update.
To participate in this conference call, dial 1-855-217-7942
(USA) or +1-646-254-3374 (International), and enter passcode
9629643. A live webcast of the conference call can be accessed on
the Investor Relations section of the Auris Medical website at
www.aurismedical.com. A replay will be available approximately two
hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in otolaryngology. The Company is currently
focusing on the development of treatments for acute inner ear
tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by
way of intratympanic injection with biocompatible gel formulations.
In addition, Auris Medical is pursuing early-stage research and
development projects. The Company was founded in 2003 and is
headquartered in Zug, Switzerland. The shares of the parent company
Auris Medical Holding AG trade on the NASDAQ Global Market under
the symbol "EARS".
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
HUG#2009441
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Oct 2023 to Oct 2024